Report Details

China TAVR & TMV Market: Insights & Forecast with Potential Impact of COVID-19 (2022-2026)

  • Published: 7th Jun 2022
  • Pages: 74
  • Format : Pdf

China TAVR market is expected to reach US$1,669.14 million in 2026, growing at a CAGR of 55.50%, for the duration spanning 2022-2026. While, the TMV market in China is forecasted to reach US$741.24 million in 2026, rising at a CAGR of 147.16%, for the time period of 2022-2026. Factors such as growing prevalence of aortic stenosis, rise in approval of new TAVR products, rise in geriatric population and rapid urbanization would drive the growth of the market. However, the market growth would be challenged by risks associated with TAVR procedures and challenge of patient selection in TMVI. A few notable trends may include rising penetration of TAVR and TMV procedures, decline in prices of transcatheter mitral valve procedures, upcoming major TMVI products and rise in complications in open-heart surgery. 

Currently, interventional heart valve therapy is advancing rapidly and is considered as a safe and minimal invasive treatment suitable for elderly patients with high surgical risks, poor health and other complications. With technology development, indications for interventional therapy are broadening.

In particular, driven by China’s favorable policy encouraging innovative medical devices, a growing number of medical device companies have joined the competition of R&D of transcatheter heart valve repair and replacement products in China. Growth in the R&D activities among major players in the country would drive the new products launch and would propel the TAVR and TMV market in China. 

Scope of the report:

The report provides a comprehensive analysis of the China TAVR and TMV Market

The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth. 

The competitive landscape of the market, along with the company profiles of leading players (Medtronic PLC, Edwards Lifesciences, Venus MedTech HangZhou Inc., MicroPort CardioFlow Medtech Corporation and Peijia Medical) are also presented in detail.

Key Target Audience:

TAVR and TMV Products Manufacturers 

Raw Material Suppliers 

End Users (Hospitals, Surgical centers and Medical Institutes) 

Research and Development Firms

Medical Technology Companies 

Investment Banks

Government Bodies & Regulating Authorities

Interested in this report?
Get your FREE sample now!

Fill the form below to get the sample report

Fill the form below to get the sample report